Evidence map›Paper›PMID 37170275›Full record

ArticleBMC urology2023

Immunohistochemical expression of the hepatocyte growth factor in chromophobe renal cell carcinoma.

Maximilian Erlmeier, Marie Mikuteit, Stefanie Zschäbitz, Michael Autenrieth, Wilko Weichert, Arndt Hartmann, Sandra Steffens, Franziska Erlmeier

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 1 country.

Maximilian ErlmeierDepartment of Urology, München Klinik Bogenhausen, Munich, Germany.
Marie MikuteitDepartment for Rheumatology and Immunology, Hannover Medical School, Carl-Neuberg-Straße 1, 30625, Hannover, Germany. Mikuteit.marie@mh-hannover.de.
Stefanie ZschäbitzDept. of Medical Oncology, National Center of Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.
Michael AutenriethDepartment of Urology, Technical University of Munich, Klinikum Rechts der Isar, München, Germany.
Wilko WeichertInstitute for Pathology and Pathological Anatomy, Technical University Munich, Munich, Germany.
Arndt HartmannInstitute of Pathology, University Hospital of Erlangen, Erlangen, Germany.
Sandra Steffens *Department for Rheumatology and Immunology, Hannover Medical School, Carl-Neuberg-Straße 1, 30625, Hannover, Germany.
Franziska Erlmeier *Institute of Pathology, University Hospital of Erlangen, Erlangen, Germany.
Universitätsklinikum Erlangen · DEHeidelberg University · DEMedizinische Hochschule Hannover · DEMünchen Klinik Bogenhausen · DETechnical University of Munich · DEUniversity Hospital Münster · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe prognostic value of Hepatocyte growth factor (HGF) in non-clear cell renal cell carcinoma (RCC) is still unclear. The aim of this study is to evaluate the prognostic impact of HGF expression in a large cohort of chromophobe RCC (chRCC).

methodsPatients who underwent renal surgery due to chRCC were recruited. Clinical data was retrospectively evaluated. Tumor specimen were analyzed for HGF expression by immunohistochemistry.

results81 chRCC patients were eligible for analysis, thereof 37 (45.7%) patients were positive for HGF. No significant associations were found for HGF expression and clinical attributes in patients with chRCC. Kaplan-Meier analysis revealed no differences in 5-year overall survival (OS) for patients with HGF

conclusionsIn chRCC HGF expression is not associated with parameters of aggressiveness or survival.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsBiomarkers, TumorHepatocyte Growth FactorHumansPrognosisRetrospective StudiesBiomarkers, TumorHepatocyte Growth FactorChromophobe histologyHGFRenal Cell CarcinomaSurvival

Identifiers

PMID37170275
PMCPMC10176764
OpenAlexW4376134546

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.